WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 2024 Healthcare Conference in Boston, MA on September 4 at 3:00 p.m. ET; Morgan Stanley 22nd Annual Global Healthcare Conference in New York, ...

WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera sold and issued 2,830,533 shares of its common ...

Kymera Therapeutics, Inc. (KYMR) announced the pricing of its underwritten public offering of $225 million of shares of its common stock. The company is selling approximately 2 million shares of common stock at a public offering price of $40.75 per share. In addition, it is selling pre-funded warrants to purchase 3.5 million shares in the offering in lieu of common stock to certain investors. The pre-funded warrants are being sold at a public offering price of $40.7499 per pre-funded warrant. This offering ...

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,002,313 shares of common stock and, in lie ...

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warra ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants Justine Koenigsberg - Vice President, Investor Relations Nello Mainolfi - Founder, President & CEO Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Eric Joseph - J.P. Morgan Jeff Jones - Oppenheimer Kelly Shi - Jefferies Vikram Purohit - Morgan Stanley Brad Canino - Stifel Nicolaus Marc Frahm - TD Cowen Kalpit Patel - B. Riley Paul Je ...

Kymera Therapeutics, Inc. (KYMR) reported a loss of 58 cents per share in the second quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 69 cents. In the year-ago quarter, Kymera reported a loss of 67 cents per share. Loss narrowed in the quarter due to higher revenues. Collaboration revenues totaled $25.6 million, which beat the Zacks Consensus Estimate of $12 million. The reported figure increased 55.3% from the year-ago quarter's level. Collaboration revenues in the second quarter we ...

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15.94%. A quarter ago, it was expected that this company would post a loss of $0.73 per share when it actually produced a loss of $0.69, delivering a surprise of 5.48%. Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------- ...

Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following interim analysis of safety and efficacy data STAT6 degrader program on track to initiate Phase 1 in second half of 2024 with data in first half of 2025; TYK2 degrader program on track to initiate and complete Phase 1 in 2025 Data from KT-253 (MDM2) and KT-333 ( ...